BSH 2022 | How novel agents are transforming the treatment landscape of SCD
Subarna Chakravorty
• 4 Apr 2022
Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, shares some insights into the current and future treatment landscape of sickle cell disease (SCD). Dr Chakravorty first gives an overview on the history of SCD and explains that the development of drugs in this area has been slow. Dr Chakravorty then discusses some of the new agents that have been approved for SCD, such as crizanlizumab, and the promise that these novel agents will have for the future treatment of SCD. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Advisory board – GBT, Forma, Novartis
